Medications Safety Information & Disclaimer
Last updated: September 2025
This page summarizes important safety information for several prescription weight‑management and diabetes medications. It is not comprehensive. Always read the full prescribing information, follow your provider’s directions and consult them before making any changes to your treatment. In an emergency, call 911 or your local emergency services. Sharing injection pens or vials can transmit infections and should never occur.
General Considerations for GLP‑1 Receptor Agonists
- Thyroid C‑cell tumors: GLP‑1 receptor agonists (including tirzepatide and semaglutide) caused thyroid tumors in rodents. It is not known whether they cause these tumors in humans. Do not use these medications if you or a family member has ever had medullary thyroid carcinoma (MTC) or if you have Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Seek medical advice if you develop a lump or swelling in your neck, hoarseness, trouble swallowing or shortness of breath, as these may be symptoms of thyroid cancer.
- Pregnancy and breastfeeding: These medicines may harm an unborn baby and are generally not recommended during pregnancy or while breastfeeding. Your provider may advise you to stop therapy several weeks before a planned pregnancy.
- Drug interactions: GLP‑1 receptor agonists slow gastric emptying and may affect the absorption of oral medications. Tell your provider about all medications (prescription, over‑the‑counter and herbal supplements) you take. Concomitant use with other GLP‑1 receptor agonists, tirzepatide‑ or semaglutide‑containing products, or other weight‑loss drugs is not recommended.
- Blood sugar and hypoglycaemia: These medications can lower blood sugar. Patients with type 2 diabetes taking insulin or sulfonylureas should monitor blood sugar closely to avoid hypoglycaemia.
Zepbound® (tirzepatide) Safety Information
Warning: Risk of Thyroid C‑Cell Tumors
- Tirzepatide injection may increase the risk of thyroid tumors. In rats, the drug caused thyroid tumors; the risk in humans is unknown. Patients and caregivers should watch for a lump or swelling in the neck, hoarseness, difficulty swallowing or shortness of breath.
- Contraindications: Do not use Zepbound if you or a family member has ever had MTC or if you have MEN 2.
FDA‑Approved Use
Zepbound (tirzepatide) is a GLP‑1/GIP receptor agonist used with a reduced‑calorie diet and increased physical activity for chronic weight management in adults with:
- Obesity: body‑mass index (BMI) ≥ 30 kg/m²; or
- Overweight: BMI ≥ 27 kg/m² with at least one weight‑related comorbidity such as hypertension, dyslipidaemia, type 2 diabetes, obstructive sleep apnoea or cardiovascular disease.
Limitations of Use
- Zepbound has not been studied in patients with a history of pancreatitis.
- It should not be used together with other tirzepatide‑containing products or any other GLP‑1 receptor agonist.
- The safety and efficacy of co‑administration with other weight‑loss products (including herbal supplements) have not been established.
Who Should Not Use Zepbound?
Do not use Zepbound if:
- You or a family member has ever had MTC or if you have MEN 2.
- You have a known allergic reaction to tirzepatide.
Administration and Dosing
Tirzepatide comes as a pre‑filled pen or vial for subcutaneous injection. Inject the dose into the abdomen, thigh or upper arm once a week at the same time each week; rotate injection sites. Your provider will usually start with a low dose and may increase it every four weeks. Do not change your dosing schedule without discussing it with your provider.
What to Tell Your Provider Before Use
Inform your provider about all medications you take and any medical conditions. In particular, mention if you:
- Have diabetes and take insulin or sulfonylureas; combining these drugs may increase the risk of low blood sugar.
- Take oral medications that might be affected by delayed gastric emptying.
- Use hormonal birth control; tirzepatide may reduce the effectiveness of oral contraceptives.
- A barrier or non‑oral method of contraception is recommended for four weeks after starting or increasing your dose.
- Have a history of pancreatitis, gallbladder disease, kidney disease, diabetic retinopathy, depression or suicidal thoughts.
- Are pregnant, planning to become pregnant or breastfeeding.
Serious Side Effects
While serious adverse events are uncommon, you or a caregiver should monitor for:
- Thyroid tumors: see warning above.
- Severe gastrointestinal disease: persistent nausea, vomiting, diarrhoea, constipation or stomach pain may indicate a serious GI disorder.
- Pancreatitis: severe abdominal pain that does not go away, sometimes radiating to the back, with or without vomiting.
- Acute kidney injury: severe dehydration from vomiting or diarrhoea can lead to kidney problems. Drink plenty of water to reduce this risk.
- Gallbladder disease: upper abdominal pain, fever, yellowing of the skin or eyes or clay‑coloured stools.
- Low blood sugar (hypoglycaemia) when used with other diabetes medications; signs include dizziness, blurred vision, sweating and fast heartbeat.
- Diabetic retinopathy and vision changes.
- Serious allergic reactions, including swelling of the face, lips, tongue or throat, rash, difficulty breathing or swallowing.
- Suicidal thoughts or mood changes; report new or worsening mental health symptoms.
Common Side Effects
The most frequently reported side effects include nausea, diarrhoea, vomiting, constipation, stomach pain, indigestion, injection‑site reactions, tiredness, belching, hair loss and heartburn.
Additional Information
Patients are encouraged to report negative side effects to the FDA’s MedWatch programme (1‑800‑FDA‑1088). This information is not comprehensive; review the full prescribing information for complete details.
Wegovy® (semaglutide) Safety Information
Warning: Risk of Thyroid C‑Cell Tumors
- In rodent studies, semaglutide (the active ingredient in Wegovy) caused thyroid tumors. It is not known whether Wegovy causes thyroid tumors or medullary thyroid carcinoma (MTC) in people.
- Contraindications: Do not use Wegovy if you or a family member has ever had MTC or if you have MEN 2.
FDA‑Approved Use
Wegovy is an injectable prescription medicine used with a reduced‑calorie diet and increased physical activity:
- To reduce major cardiovascular events (death, heart attack or stroke) in adults with obesity or overweight and known heart disease.
- For chronic weight management in adults with obesity (BMI ≥30 kg/m²), adults with overweight (BMI ≥27 kg/m²) and at least one weight‑related comorbidity, and children aged ≥12 years with obesity.
- Wegovy contains semaglutide and should not be used with other semaglutide‑containing products or other GLP‑1 receptor agonists.
Limitations of Use
- Wegovy has not been studied in patients with a history of pancreatitis.
- Safety and efficacy of co‑administration with other weight‑loss products have not been established.
- It is not known if Wegovy is safe and effective in children under 12 years of age.
Who Should Not Use Wegovy?
Do not use Wegovy if:
- You or a family member has ever had MTC or if you have MEN 2.
- You have had a serious allergic reaction to semaglutide or any of the ingredients in Wegovy.
Administration and Dosing
Wegovy comes as a pre‑filled pen for weekly subcutaneous injection. Inject into the abdomen, thigh or upper arm once a week on the same day each week; rotate injection sites. Your provider will usually start at a low dose and increase it over several weeks. Do not change your dosing regimen or stop therapy without consulting your provider.
What to Tell Your Provider Before Use
Inform your provider if you:
- Have problems with your pancreas, gallbladder, kidneys, stomach or intestines, or have a history of diabetic retinopathy.
- Have depression or suicidal thoughts.
- Are pregnant or plan to become pregnant; Wegovy may harm your unborn baby and should be stopped at least two months before a planned pregnancy.
- Are breastfeeding; it is not known if semaglutide passes into breast milk.
- Take other medications, especially those that lower blood sugar (such as insulin or sulfonylureas) or are taken orally.
Serious Side Effects
Monitor for the following serious side effects and contact your provider if they occur:
- Pancreatitis: severe stomach pain that does not go away and may radiate to the back.
- Gallbladder disease: upper abdominal pain, fever, yellowing of the skin or eyes (jaundice) or clay‑coloured stools.
- Low blood sugar: particularly in patients also taking insulin or sulfonylureas; symptoms include dizziness, blurred vision, mood changes, sweating, slurred speech, hunger, confusion or rapid heartbeat.
- Kidney problems due to dehydration: drink fluids to avoid dehydration if diarrhoea or vomiting occurs.
- Severe stomach problems: persistent stomach pain or discomfort.
- Serious allergic reactions: swelling of the face, lips, tongue or throat; difficulty breathing or swallowing; severe rash or itching; fainting or very rapid heartbeat.
- Vision changes (diabetic retinopathy).
- Increased heart rate: resting heart palpitations.
- Depression or suicidal thoughts: new or worsening mental health symptoms.
- Aspiration risk during surgery: Wegovy may increase the chance of food getting into the lungs during procedures requiring anaesthesia; tell all healthcare providers that you are taking Wegovy.
Common Side Effects
The most common side effects include nausea, diarrhoea, vomiting, constipation, stomach pain, headache, tiredness, upset stomach, dizziness, feeling bloated, belching, low blood sugar in people with type 2 diabetes, gas, stomach flu, heartburn and runny nose or sore throat.
Additional Information
Report adverse effects to the FDA’s MedWatch programme. Review the full prescribing information and medication guide for complete details. Wegovy is a registered trademark of Novo Nordisk. ZenovaMD has no affiliation with Novo Nordisk.
Mounjaro® (tirzepatide) Safety Information
Warning: Risk of Thyroid C‑Cell Tumors
- Tirzepatide may increase the risk of thyroid tumors; this risk has been observed in animals. It is unknown whether Mounjaro causes thyroid tumors in humans. Watch for a lump or swelling in the neck, hoarseness, trouble swallowing or shortness of breath and report these symptoms to your provider.
- Contraindications: Do not use Mounjaro if you or a family member has ever had MTC or if you have MEN 2.
FDA‑Approved Use
Mounjaro is an injectable GLP‑1/GIP receptor agonist used along with diet and exercise to improve glycaemic control in adults with type 2 diabetes. It is not approved for use in people with type 1 diabetes. The safety and efficacy in children under 18 years of age are unknown.
Limitations of Use
- Mounjaro is not indicated for weight loss, although some patients may lose weight. It has not been studied in patients with a history of pancreatitis.
- Do not use Mounjaro together with other tirzepatide‑containing products or other GLP‑1 receptor agonists.
Who Should Not Use Mounjaro?
Do not use Mounjaro if:
- You or a family member has ever had MTC or if you have MEN 2.
- You are allergic to tirzepatide.
Administration and Dosing
Mounjaro is injected subcutaneously once weekly into the abdomen, thigh or upper arm. Rotate injection sites each week; do not use the same site for every injection. Your provider will start at a low dose and may increase the dose every four weeks. Do not change your dose without consulting your provider.
What to Tell Your Provider Before Use
Before starting Mounjaro, tell your provider about all medications and supplements you take and whether you:
- Have type 1 diabetes; Mounjaro is not for type 1 diabetes.
- Have kidney disease, gallbladder disease, pancreatitis or severe gastrointestinal disease.
- Have diabetic retinopathy or vision problems.
- Use oral contraceptives; tirzepatide may reduce their effectiveness. Use a non‑oral method or barrier contraception for four weeks after starting or increasing your dose.
- Are pregnant, planning to become pregnant or breastfeeding.
- Take other diabetes medications such as insulin or sulfonylureas (risk of low blood sugar)..
Serious Side Effects
Monitor for the following serious side effects:
- Thyroid tumors (see boxed warning).
- Pancreatitis: sudden severe abdominal pain with or without vomiting.
- Gallbladder disease: upper abdominal pain, yellowing of the skin or eyes, fever or clay‑coloured stools.
- Acute kidney injury: signs include decreased urine output, swelling, rapid weight gain or tiredness.
- Severe gastrointestinal problems: persistent severe stomach pain or bowel issues.
- Diabetic retinopathy and vision changes.
- Low blood sugar (hypoglycaemia): particularly when combined with insulin or sulfonylureas.
- Serious allergic reactions such as swelling of the face, lips, tongue or throat, difficulty breathing, severe rash or itching.
- Mental health changes, including depression or suicidal thoughts..
Common Side Effects
Common adverse effects include nausea, diarrhoea, vomiting, constipation, stomach pain, indigestion, injection‑site reactions, tiredness, belching, hair loss and heartburn.
Additional Information
Patients should report side effects to the FDA. Review the complete prescribing information for full details. Mounjaro is a registered trademark of Eli Lilly and Company; ZenovaMD Health is not affiliated with Eli Lilly.
Ozempic® (semaglutide) Safety Information
Warning: Risk of Thyroid C‑Cell Tumors
- Semaglutide injection may increase the risk of thyroid tumors; this was observed in rats. It is not known if Ozempic causes thyroid tumors or medullary thyroid carcinoma (MTC) in people.
- Contraindications: Do not use Ozempic if you or a family member has ever had MTC or if you have MEN 2.
FDA‑Approved Use
Ozempic (semaglutide) injection 0.5 mg, 1 mg or 2 mg is an injectable prescription medicine used:
- Along with diet and exercise to improve blood sugar in adults with type 2 diabetes.
- To reduce the risk of major cardiovascular events (heart attack, stroke or death) in adults with type 2 diabetes and known heart disease.
- Ozempic is not for use in people with type 1 diabetes and has not been studied in children under 18 years of age.
Limitations of Use
- Ozempic should not be used with other semaglutide‑containing products or other GLP‑1 receptor agonists.
- It has not been studied in patients with a history of pancreatitis.
Who Should Not Use Ozempic?
Do not use Ozempic if:
- You or a family member has ever had MTC or if you have MEN 2.
- You are allergic to semaglutide or any of the ingredients in Ozempic.
Administration and Dosing
Ozempic is injected once weekly under the skin of the abdomen, thigh or upper arm. Rotate injection sites and use a new needle each time. Your provider will start at a low dose and may increase it every four weeks. Do not change your dosing regimen without medical advice.
What to Tell Your Provider Before Use
Before starting Ozempic, inform your provider if you:
- Have or have ever had pancreatitis, gallbladder disease, kidney disease, diabetic retinopathy, depression or suicidal thoughts.
- Are pregnant, planning a pregnancy or breastfeeding.
- Take other medications, including insulin or sulfonylureas (risk of hypoglycaemia) or any oral medicines that may be affected by delayed gastric emptying.
- Use oral contraceptives; semaglutide may reduce the efficacy of hormonal birth control. A barrier or non‑oral method is recommended for four weeks after starting or increasing the dose.
Serious Side Effects
Possible serious side effects include:
- Thyroid tumors (see boxed warning).
- Pancreatitis: severe abdominal pain that does not go away.
- Gallbladder disease: upper abdominal pain, jaundice or clay‑coloured stools.
- Acute kidney injury from dehydration due to diarrhoea, nausea or vomiting.
- Severe gastrointestinal problems, including persistent stomach pain or discomfort.
- Low blood sugar: particularly when used with insulin or sulfonylureas.
- Serious allergic reactions, including swelling of the face, lips, tongue or throat; difficulty breathing; severe rash or itching; or very rapid heartbeat.
- Vision changes, increased heart rate and depression or suicidal thoughts.
Common Side Effects
Common side effects include nausea, diarrhoea, vomiting, constipation, stomach pain, indigestion, injection‑site reactions, tiredness, belching, hair loss and heartburn.
Additional Information
Report adverse effects to the FDA’s MedWatch programme. Read the full prescribing information. Ozempic is a registered trademark of Novo Nordisk; ZenovaMD is not affiliated with Novo Nordisk.
Saxenda® (liraglutide) Safety Information
Warning: Risk of Thyroid C‑Cell Tumors
- Liraglutide injection may increase the risk of thyroid tumors. In studies with rats and mice, liraglutide and similar medicines caused thyroid tumors. It is unknown whether Saxenda causes thyroid tumors in humans.
- Contraindications: Do not use Saxenda if you or a family member has ever had MTC or if you have MEN 2.
FDA‑Approved Use
Saxenda is an injectable prescription medicine used:
- For adults with obesity (BMI ≥30 kg/m²) or overweight (BMI ≥27 kg/m²) who also have weight‑related medical problems, and
- For adolescents aged 12‑17 years with a body weight ≥ 60 kg and obesity,
as an adjunct to a reduced‑calorie diet and increased physical activity to help them lose weight and keep it off.
Limitations of Use
- Saxenda is not recommended for people taking other liraglutide‑containing products (such as Victoza) or any other GLP‑1 receptor agonists.
- It is not known if Saxenda is safe and effective in children under 12 years of age or in adolescents with type 2 diabetes.
Who Should Not Use Saxenda?
Do not use Saxenda if:
- You or a family member has ever had MTC or if you have MEN 2.
- You have had a serious allergic reaction to liraglutide or any of its ingredients.
Administration and Dosing
Saxenda is injected subcutaneously once daily into the abdomen, thigh or upper arm. Rotate injection sites to reduce the risk of cutaneous amyloidosis. Use a new needle for each injection and do not share your pen. Follow the dosing schedule provided by your provider.
What to Tell Your Provider Before Use
Before starting Saxenda, tell your provider if you:
- Have problems with your pancreas, severe stomach problems (such as gastroparesis) or difficulty digesting food.
- Have depression, suicidal thoughts or other mental health issues.
- Are pregnant or plan to become pregnant (Saxenda should not be used during pregnancy) or are breastfeeding (it is not known if Saxenda passes into breast milk.
- Take diabetes medications (insulin or sulfonylureas) or other medicines; Saxenda may affect or be affected by other drugs.
Serious Side Effects
Saxenda may cause serious side effects, including:
- Thyroid tumors (see boxed warning).
- Pancreatitis: severe abdominal pain that will not go away, with or without vomiting.
- Low blood sugar: particularly in adults with type 2 diabetes or adolescents without diabetes.
- Increased heart rate: resting heart palpitations.
- Kidney problems from dehydration: diarrhoea, nausea and vomiting can cause fluid loss.
- Severe stomach problems: persistent stomach pain.
- Serious allergic reactions: swelling of the face, lips, tongue or throat; rash; fainting or very rapid heartbeat.
- Gallbladder problems: pain in the upper abdomen, fever, jaundice or clay‑coloured stools.
- Depression or suicidal thoughts.
- Aspiration risk during surgery: tell all healthcare providers that you are taking Saxenda before any procedure requiring anaesthesia.
Common Side Effects
Common side effects include nausea, diarrhoea, constipation, vomiting, stomach pain, indigestion, injection‑site reactions, tiredness, allergic reactions, belching, hair loss and heartburn. Fever and gastroenteritis are additional common side effects in children.
Additional Information
Report adverse effects to the FDA. Read the full prescribing information for complete details. Saxenda is a registered trademark of Novo Nordisk; ZenovaMD has no affiliation with Novo Nordisk.
Compounded Semaglutide Safety Information
Compounded semaglutide is a custom‑made formulation that is not approved by the U.S. Food and Drug Administration (FDA). The FDA does not review compounded drugs for safety, effectiveness or quality before they are marketed. Compounded products should only be used when a patient’s medical needs cannot be met by an FDA‑approved drug. The following information summarizes potential risks; it does not replace advice from your healthcare provider.
Indications
Compounded semaglutide may be prescribed by a licensed healthcare provider to assist with weight management in adults and adolescents with obesity (BMI ≥27 kg/m²) who may also have weight‑related medical problems. It should be used along with a reduced‑calorie diet and increased physical activity.
Limitations of Use
- Compounded semaglutide should not be used in combination with any other semaglutide‑containing product or GLP‑1/GIP receptor agonist.
- Its safety and efficacy have not been established. Compounded drugs are not evaluated by the FDA for safety, effectiveness or manufacturing quality.
- It is not known if compounded semaglutide can be used in people who have had pancreatitis or in children under 18 years of age.
Who Should Not Use Compounded Semaglutide
Do not use compounded semaglutide if:
- You or a family member has ever had medullary thyroid carcinoma or if you have MEN 2 (risk of thyroid tumors, as observed with semaglutide).
- You are allergic to semaglutide.
Administration and Dosing
Compounded semaglutide is typically supplied in a multi‑dose vial and administered by subcutaneous injection once weekly. Your provider will instruct you on how to draw up and inject the medication using a needle and syringe and may adjust your dose every four weeks. Do not change your dosing regimen without consulting your provider. Rotate injection sites (abdomen, thigh or upper arm). Never share vials or syringes; sharing can spread infection.
What to Tell Your Provider Before Use
Tell your provider about all medications you take and any medical conditions. In particular, disclose if you:
- Have type 1 or type 2 diabetes, thyroid cancer, pancreatitis, kidney disease, diabetic retinopathy, depression or suicidal thoughts.
- Take insulin or sulfonylureas (increases risk of low blood sugar).
- Are pregnant, plan to become pregnant or breastfeeding; compounded semaglutide should not be used during pregnancy and is not recommended during breastfeeding.
Potential Benefits and Risks of Micro‑Dosing
Some providers may prescribe micro‑doses of compounded semaglutide for patients who experience side effects at higher doses or for off‑label goals such as improving cardiovascular risk factors or inflammatory conditions. These uses are experimental and not FDA‑approved. Evidence of benefit is limited, and risks such as thyroid tumors, pancreatitis, gallbladder disease, kidney injury, low blood sugar and mental health changes may still occur (see serious side effects under Ozempic/Wegovy above).
Adverse Effects and Safety Concerns
- Thyroid tumors: semaglutide caused thyroid tumors in rats.
- Pancreatitis, gallbladder disease, kidney injury and severe gastrointestinal side effects: see Ozempic/Wegovy safety information above.
- Hypoglycaemia when used with other diabetes medications.
Serious allergic reactions.
The FDA has received reports of dosing errors and adverse events with compounded semaglutide, some requiring hospitalization. Dosing errors may occur when patients measure or administer an incorrect dose. Work closely with your provider and pharmacy to ensure proper dosing and storage.
Additional Information
Carefully check labels to ensure your medicine is provided by a licensed pharmacy. Do not use any injectable compounded semaglutide that arrives warm or with insufficient refrigeration. Discuss any concerns with your provider. Compounded semaglutide is not manufactured by Novo Nordisk or any company affiliated with Novo Nordisk; ZenovaMD is not affiliated with Novo Nordisk.
Compounded Tirzepatide Safety Information
Compounded tirzepatide is a custom formulation not approved by the FDA. The FDA does not evaluate compounded drugs for safety, effectiveness or manufacturing quality. Use compounded tirzepatide only when no FDA‑approved alternatives meet your medical needs and only under the supervision of a licensed healthcare provider.
Indications
Compounded tirzepatide may be prescribed for adults and adolescents with obesity (BMI ≥27 kg/m²) who have weight‑related medical problems and as part of a reduced‑calorie diet and increased physical activity. It is also under investigation for other potential benefits at low (micro) doses. These uses are experimental and not FDA‑approved.
Limitations of Use
- Do not use compounded tirzepatide with other tirzepatide‑containing products or any other GLP‑1/GIP receptor agonist.
- Safety and efficacy have not been established. The product is not reviewed by the FDA.
- It is not known if compounded tirzepatide can be used in people with pancreatitis or in children under 18 years of age.
Who Should Not Use Compounded Tirzepatide
Do not use compounded tirzepatide if:
- You or a family member has ever had MTC or if you have MEN 2 (risk of thyroid tumors).
- You have a known allergy to tirzepatide.
Administration and Dosing
Compounded tirzepatide is supplied in a vial for subcutaneous injection once weekly. Your provider will instruct you on drawing and injecting the medication and may adjust your dose every four weeks. Rotate injection sites and never share vials or syringes. Do not change your dosing schedule without consulting your provider.
What to Tell Your Provider Before Use
Inform your provider about all medications you take and any medical history, particularly if you:
- Have type 1 or type 2 diabetes, thyroid cancer, pancreatitis, kidney disease, diabetic retinopathy, depression or suicidal thoughts.
- Take insulin or sulfonylureas (risk of low blood sugar).
- Are pregnant or planning pregnancy; compounded tirzepatide should not be used during pregnancy and should be discontinued at least two months before a planned pregnancy.
- Are breastfeeding; it is not known if compounded tirzepatide passes into breast milk.
Potential Benefits and Risks of Micro‑Dosing
Micro‑doses of compounded tirzepatide may be used experimentally for conditions such as reducing cardiovascular risk or inflammation. These benefits are not proven. Serious side effects similar to those seen with tirzepatide (see Mounjaro/Zepbound safety information above) can still occur, including thyroid tumors, pancreatitis, gallbladder disease, kidney injury, severe gastrointestinal problems, hypoglycaemia, vision changes and mental health effects.
Adverse Effects and Safety Concerns
- Thyroid tumors: tirzepatide caused thyroid C‑cell tumors in rats.
- Pancreatitis, gallbladder disease, kidney injury, severe gastrointestinal problems and hypoglycaemia: see Mounjaro/Zepbound safety information above.
- Serious allergic reactions and mental health changes.
The FDA has received reports of dosing errors and adverse events associated with compounded tirzepatide. Work with your provider and pharmacy to ensure proper dosing.
Additional Information
Our compounded tirzepatide is dispensed by a licensed pharmacy. Compounded tirzepatide is not manufactured by Eli Lilly or any company affiliated with Eli Lilly; ZenovaMD is not affiliated with Eli Lilly.
Legal and Trademark Notice
Ozempic®, Wegovy®, Saxenda® and Victoza® are registered trademarks of Novo Nordisk A/S. Zepbound® and Mounjaro® are registered trademarks of Eli Lilly and Company. ZenovaMD has no affiliation with Novo Nordisk or Eli Lilly, and the compounded products offered through our programme are not made by or associated with these companies. This website is for informational purposes only and does not provide medical advice. Always consult a healthcare professional for diagnosis and treatment.
